The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
December 26th 2024
From groundbreaking therapies to ethical dilemmas, HCPLive’s top podcasts of 2024 delivered expert insights and human stories across medicine.
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)
View More
Determining Risky Blood Pressure in Children and Adolescents
September 26th 2014Determining if a child or adolescent has hypertension is complex and requires use of gender, age, and height specific readings. This study used a simplified approach of systolic and diastolic blood pressure readings compared to height as a screening tool for the diagnosis of hypertension in Chinese children.
More Data on Beta-Blockers in Patients with Heart Failure and Atrial Fibrillation
New research indicates that atrial fibrillation (AF) eliminates the benefits that treatment with beta-blockers otherwise produces in patients with heart failure and reduced ejection fraction (HFrEF).
FDA Approves Celgene's PDE4 Inhibitor Otezla for the Treatment of Plaque Psoriasis in Adults
September 23rd 2014Otezla (apremilast) is an oral, selective phosphodiesterase 4 (PDE4) inhibitor for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
Debate: Best Beta-Blockers for Long QT?
Is one beta blocker better than another for patients born with long QT syndrome? In a report published in The Journal of the American College of Cardiology, Abeer Abu-Zeitone, PhD, and colleagues found that in their study group, nadolol worked best at preventing a recurrent serious cardiac event and that propranolol, the oldest beta-blocker available, did the worst.
Cardiac Intervention Guidelines Get Update
The American College of Cardiology (ACC) has had a change of heart. The group is now recommending doctors treating heart attack patients for arterial blockages should treat lesions in both cardiac arteries, not just the "culprit" artery that led to the MI.
What is the Role of Denervation Following the Publication of the SYMPLICITY HTN-3 Trial Results
September 19th 2014In this edition of Clinical Forum, we asked 3 Cardiology Review editorial board members to comment on the role of renal denervation following the publication of the SYMPLICITY HTN-3 trial results.
What Does the Future Hold for a Once Promising Hypertension Treatment
September 19th 2014In their recent article published in the Journal of the American College of Cardiology, Vivek Y. Reddy, MD, and Jeffrey W. Olin, DO, noted "there are few areas in medicine that have gained as much prominence as quickly, or have been as widely dismissed as quickly, as catheter-based renal sympathetic denervation for the treatment of resistant hypertension.
American Diabetes Association 74th Scientific Sessions
September 19th 2014The 74th Scientific Sessions of the American Diabetes Association (ADA) brought together more than 17,300 attendees from more than 121 countries. This year's program included 96 symposia, 50 oral abstract sessions, 10 interest group discussions, 18 meet-the-expert sessions, and 10 special lectures and addresses. Cardiology Review is covering 6 of the top sessions.
Study: Healthy Living Beats Drugs for Heart Attack Prevention
Despite the availability of lipid-lowering and antihypertensive drugs, lifestyle changes could prevent 79% of myocardial infarction (MI) in men, a Swedish study found. The drugs can be effective but "adherence to a healthy lifestyle still has an impressive impact" and avoids any pharmalogical side effects, according Agneta Akesson, PHD, of the Institute of Environmental Medicine in Stockholm, Sweden. Writing in the Journal of the American College of Cardiology[link TK], Akesson concludes that "A healthy diet together with low-risk lifestyle practices and absence of abdominal adiposity may prevent the vast majority of MI events in men."
Insulin Pumps Show Benefits Beyond Convenience
Patients diagnosed with type 1 diabetes have long known the benefits of ease and convenience that comes with using an insulin pump instead of relying on multiple daily insulin injections to control their condition. A recent study has shown that using a pump is also associated with positive effects on long-term cardiovascular risk and mortality.
New Test Finds Diabetes' Silent Heart Damage
Using an experimental and highly sensitive test for cardiac troponin, a team of Johns Hopkins researchers found undetected signs of heart muscle damage in people with diabetes and pre-diabetes. That may suggest that hypoglycemia directly damages the heart.